To follow-up on the canine discoveries, we inspected variants in RNF207 and PRKAA2 in three human cohorts: first, 721 cardiomyopathy patients that underwent diagnostic cardiovascular whole-exome-based genetic testing; second, UK Biobank participants affected by DCM; and third, the FinnGen Consortium (https://r8.finngen.fi/). This evidence concerns the gene RNF207 and cardiomyopathy.